Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Return on Equity (2016 - 2020)

Historic Return on Equity for Larimar Therapeutics (LRMR) over the last 7 years, with Q3 2020 value amounting to 0.1%.

  • Larimar Therapeutics' Return on Equity rose 7000.0% to 0.1% in Q3 2020 from the same period last year, while for Sep 2020 it was 0.1%, marking a year-over-year increase of 7000.0%. This contributed to the annual value of 0.98% for FY2019, which is 2700.0% down from last year.
  • Per Larimar Therapeutics' latest filing, its Return on Equity stood at 0.1% for Q3 2020, which was up 7000.0% from 0.29% recorded in Q2 2020.
  • Larimar Therapeutics' 5-year Return on Equity high stood at 0.1% for Q3 2020, and its period low was 1.54% during Q4 2019.
  • Its 5-year average for Return on Equity is 0.67%, with a median of 0.62% in 2018.
  • As far as peak fluctuations go, Larimar Therapeutics' Return on Equity plummeted by -9200bps in 2019, and later skyrocketed by 7000bps in 2020.
  • Quarter analysis of 5 years shows Larimar Therapeutics' Return on Equity stood at 0.46% in 2016, then plummeted by -36bps to 0.62% in 2017, then grew by 1bps to 0.62% in 2018, then crashed by -148bps to 1.54% in 2019, then surged by 93bps to 0.1% in 2020.
  • Its Return on Equity stands at 0.1% for Q3 2020, versus 0.29% for Q2 2020 and 1.43% for Q1 2020.